REG - Cizzle Biotechnology - Notice of Annual General Meeting

Cizzle Biotechnology HoldingsAnnouncement

03/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC7441Qa&default-theme=true

RNS Number : 7441Q  Cizzle Biotechnology Holdings PLC  03 June 2024

Cizzle Biotechnology Holdings plc

("Cizzle Biotechnology", or the "Company")

Notice of Annual General Meeting

 

Cizzle Biotechnology, the UK based diagnostics developer, announces that the
notice of Annual General Meeting ("AGM"), has been sent to shareholders and is
available for viewing on the Company's website at
https://cizzlebiotechnology.com (https://cizzlebiotechnology.com) .

 

The AGM will be held at 11.00 a.m. on 24 June 2024 at the offices of
Shakespeare Martineau LLP, 6(th) Floor, 60 Gracechurch Street, London, EC3V
0HR.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited        +44(0) 20 3328 5656
 John Depasquale
 George Payne

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test to facilitate the early
detection of lung cancer based on the ability to detect a stable plasma
biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring
cell nuclear protein involved in DNA replication, and the targeted CIZ1B
variant has been shown to be highly correlated with early-stage lung cancer.
The Company's proprietary technology results from the work of Professor
Coverley and colleagues at the University of York.

For more information please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQKDBBNBKDPAK